Campbell & CO Investment Adviser LLC Has $347,000 Stock Position in Pfizer Inc. $PFE

Campbell & CO Investment Adviser LLC cut its holdings in Pfizer Inc. (NYSE:PFE) by 75.2% during the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 14,332 shares of the biopharmaceutical company’s stock after selling 43,434 shares during the quarter. Campbell & CO Investment Adviser LLC’s holdings in Pfizer were worth $347,000 at the end of the most recent reporting period.

Several other institutional investors have also recently bought and sold shares of PFE. Brighton Jones LLC increased its holdings in Pfizer by 1,282.4% in the 4th quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company’s stock worth $17,677,000 after purchasing an additional 618,117 shares in the last quarter. Revolve Wealth Partners LLC boosted its position in Pfizer by 12.5% during the 4th quarter. Revolve Wealth Partners LLC now owns 18,766 shares of the biopharmaceutical company’s stock worth $498,000 after buying an additional 2,087 shares during the period. Csenge Advisory Group grew its holdings in Pfizer by 115.8% during the 1st quarter. Csenge Advisory Group now owns 84,269 shares of the biopharmaceutical company’s stock worth $2,135,000 after acquiring an additional 45,214 shares during the last quarter. Kestra Private Wealth Services LLC increased its position in Pfizer by 1.2% in the 1st quarter. Kestra Private Wealth Services LLC now owns 299,796 shares of the biopharmaceutical company’s stock valued at $7,597,000 after acquiring an additional 3,533 shares during the period. Finally, Calton & Associates Inc. raised its stake in shares of Pfizer by 137.4% during the first quarter. Calton & Associates Inc. now owns 29,634 shares of the biopharmaceutical company’s stock valued at $751,000 after acquiring an additional 17,151 shares during the last quarter. Institutional investors and hedge funds own 68.36% of the company’s stock.

Analyst Upgrades and Downgrades

PFE has been the subject of a number of recent research reports. Bank of America increased their price objective on Pfizer from $28.00 to $30.00 and gave the company a “neutral” rating in a report on Friday, October 3rd. Wall Street Zen cut Pfizer from a “buy” rating to a “hold” rating in a report on Sunday, September 28th. Citigroup boosted their price target on shares of Pfizer from $25.00 to $26.00 and gave the stock a “neutral” rating in a research report on Wednesday, August 6th. Sanford C. Bernstein reissued a “market perform” rating and set a $30.00 target price on shares of Pfizer in a research note on Friday, October 31st. Finally, The Goldman Sachs Group reaffirmed a “neutral” rating and set a $26.00 price target on shares of Pfizer in a research report on Wednesday, November 5th. Two research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, twelve have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of “Hold” and an average target price of $28.28.

Pfizer Trading Down 2.8%

NYSE:PFE opened at $25.08 on Monday. Pfizer Inc. has a one year low of $20.92 and a one year high of $27.69. The company has a market cap of $142.57 billion, a PE ratio of 13.34, a PEG ratio of 0.81 and a beta of 0.54. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.16 and a quick ratio of 0.85. The firm has a 50-day moving average of $24.80 and a 200-day moving average of $24.45.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, November 4th. The biopharmaceutical company reported $0.87 EPS for the quarter, topping analysts’ consensus estimates of $0.79 by $0.08. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The firm had revenue of $16.65 billion during the quarter, compared to analyst estimates of $16.94 billion. Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. As a group, equities research analysts expect that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, December 1st. Shareholders of record on Friday, November 7th will be issued a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a yield of 6.9%. The ex-dividend date of this dividend is Friday, November 7th. Pfizer’s payout ratio is currently 100.00%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.